JCM
MRNA icon

Jacobi Capital Management’s Moderna MRNA Stock Holding History

Jacobi Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,686
Closed -$205K – 441
2023
Q2 		$205K Sell
1,686
-10
-0.6% -$1.33K 0.02% 421
2023
Q1 		$260K Hold
1,696
– – 0.03% 364
2022
Q4 		$305K Sell
1,696
-424
-20% -$69.3K 0.04% 339
2022
Q3 		$251K Hold
2,120
– – 0.03% 357
2022
Q2 		$303K Buy
2,120
+10
+0.5% +$1.43K 0.04% 334
2022
Q1 		$363K Buy
2,110
+100
+5% +$16.8K 0.04% 315
2021
Q4 		$510K Buy
2,010
+1,509
+301% +$441K 0.06% 271
2021
Q3 		$193K Buy
501
+45
+10% +$16.6K 0.02% 402
2021
Q2 		$107K Sell
456
-388
-46% -$69.3K 0.01% 480
2021
Q1 		$111K Sell
844
-180
-18% -$26.1K 0.02% 429
2020
Q4 		$107K Buy
1,024
+829
+425% +$83.9K 0.02% 402
2020
Q3 		$14K Buy
195
+124
+175% +$8.65K ﹤0.01% 748
2020
Q2 		$5K Sell
71
-929
-93% -$50.9K ﹤0.01% 912
2020
Q1 		$30K Buy
1,000
+500
+100% +$11.5K 0.01% 502
2019
Q4 		$10K Hold
500
– – ﹤0.01% 748
2019
Q3 		$8K Hold
500
– – ﹤0.01% 763
2019
Q2 		$7K Buy
+500
New +$10.7K ﹤0.01% 787

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Jacobi Capital Management's MRNA Position: Q3 2023 in Review

Jacobi Capital Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 1,686 shares — an estimated $205K sold.

Jacobi Capital Management first reported a position in MRNA in Q2 2019 and held it in 17 quarters. The position peaked at $510K in Q4 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Jacobi Capital Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Jacobi Capital Management sold 1,686 Moderna shares in Q3 2023, an estimated $205K.
  • Jacobi Capital Management first reported a position in Moderna in Q2 2019 and held it in 17 quarters.
  • Jacobi Capital Management's Moderna position peaked at $510K in Q4 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Jacobi Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.